Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction

Table 1 Comparison of blood lipid indexes, platelet maximum aggregation rate, and plasma viscosity between the two groups (mean ± SD)

Group		Control group (n = 41)	Observation group (n = 41)
TC (mmol/L)	Before treatment	6.52 ± 0.47	6.40 ± 0.56
	After treatment	5.17 ± 0.41a	4.79 ± 0.32a,c
TG (mmol/L)	Before treatment	2.92 ± 0.41	2.89 ± 0.45
	After treatment	2.05 ± 0.36 a	1.68 ± 0.31a,c
HDL-C (mmol/L)	Before treatment	0.96 ± 0.31	0.95 ± 0.36
	After treatment	1.67 ± 0.37a	1.95 ± 0.42a,c
LDL-C (mmol/L)	Before treatment	4.25 ± 0.56	4.21 ± 0.53
	After treatment	3.37 ± 0.45a	2.89 ± 0.39a,c
Maximum platelet aggregation rate(%)	Before treatment	75.92 ± 9.64	78.40 ± 10.22
	After treatment	46.48 ± 7.26a	58.30 ± 7.74a,c
Blood plasma viscosity (mPa·s)	Before treatment	1.86 ± 0.48	1.94 ± 0.43
	After treatment	1.40 ± 0.33a	1.61 ± 0.35a,c

^aP < 0.05 vs before treatment.

^cP < 0.05 vs the control group.

TC: Total cholesterol; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol.

Table 2 Comparison of inflammatory factors and immune levels between the two groups (mean ± SD)

Group		Control group (n = 41)	Observation group (n = 41)
hs-CRP (mg/L)	Before treatment	10.63 ± 2.58	10.49 ± 2.44
	After treatment	7.23 ± 1.96a	5.48 ± 1.67a,c
TNF-α (pg/mL)	Before treatment	58.69 ± 6.32	59.02 ± 7.44
	After treatment	46.58 ± 5.24a	37.02 ± 4.63a,c
HMGBl (µg/L)	Before treatment	5.84 ± 0.56	5.81 ± 0.59
	After treatment	3.23 ± 0.52a	2.94 ± 0.43a,c
PON-1 (U/L)	Before treatment	135.23 ± 25.21	130.58 ± 22.17
	After treatment	159.63 ± 25.74a	174.25 ± 31.02a,c
ESR (mm/h)	Before treatment	32.15 ± 5.27	30.96 ± 6.42
	After treatment	19.36 ± 3.78a	13.02 ± 4.11a,c
MIF (ng/mL)	Before treatment	84.96 ± 5.87	86.02 ± 8.11
	After treatment	76.36 ± 6.14a	68.21 ± 5.47a,c

^aP < 0.05 vs before treatment.

^cP < 0.05 vs the control group.

hs-CRP: High-sensitivity-C reactive protein; TNF-α: Tumor necrosis factor-alpha; HMGBl: High-mobility group protein B1; PON-1: Paraoxonase-1; ESR: Erythrocyte sedimentation rate; MIF: Macrophage migration inhibitory factor.